Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.8522
-0.0146 (-1.68%)
At close: Jun 3, 2025, 4:00 PM
0.8361
-0.0161 (-1.89%)
After-hours: Jun 3, 2025, 7:50 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 15 employees as of December 31, 2024. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,756,267
Market Cap
110.08M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ATOS News
- 1 day ago - Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 14 days ago - Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - Accesswire
- 20 days ago - Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - PRNewsWire
- 21 days ago - Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 4 weeks ago - Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio - GlobeNewsWire
- 5 weeks ago - Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 - GlobeNewsWire
- 6 weeks ago - Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio - GlobeNewsWire
- 7 weeks ago - Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - PRNewsWire